We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+62.61%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.17B
AUM Growth
+$385M
Cap. Flow
+$46M
Cap. Flow %
3.94%
Top 10 Hldgs %
67.93%
Holding
74
New
28
Increased
5
Reduced
17
Closed
15

Top Buys

Rank Stock Value
1
OLMA icon
Olema Pharmaceuticals
OLMA
+$176M
2
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$22.9M
3
CCCC icon
C4 Therapeutics
CCCC
+$13.9M
4
ABCL icon
AbCellera Biologics
ABCL
+$13.7M
5
COGT icon
Cogent Biosciences
COGT
+$13.7M

Top Sells

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$72.5M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$46.9M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$38.6M
4
TGTX icon
TG Therapeutics
TGTX
+$30.4M
5
CLDX icon
Celldex Therapeutics
CLDX
+$17.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRIS icon
26
Curis
CRIS
$9.41M
$9.83M 0.84%
+3,000
New +$3.6M
KALV
27
DELISTED
KalVista Pharmaceuticals
KALV
$9.3M 0.8%
490,000
+190,000
+63% +$3.26M
VRDN icon
28
Viridian Therapeutics
VRDN
$2.15B
$9.05M 0.78%
+550,000
New +$8.29M
PASG icon
29
Passage Bio
PASG
$14.7M
$8.81M 0.76%
17,222
– –
VINCU
30
DELISTED
Vincerx Pharma, Inc. Unit
VINCU
$7.7M 0.66%
+400,000
New +$7.7M
NRIX icon
31
Nurix Therapeutics
NRIX
$2.51B
$7.57M 0.65%
230,297
-44,703
-16% -$1.48M
PNT
32
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$6.96M 0.6%
500,000
– –
KYMR icon
33
Kymera Therapeutics
KYMR
$8.73B
$6.88M 0.59%
110,920
-190,000
-63% -$9.27M
EPIX
34
DELISTED
ESSA Pharma
EPIX
$6.56M 0.56%
+550,000
New +$3.87M
STTK icon
35
Shattuck Labs
STTK
$651M
$6.37M 0.55%
+121,562
New +$3.91M
PMVP icon
36
PMV Pharmaceuticals
PMVP
$58.7M
$6.15M 0.53%
100,000
-50,000
-33% -$1.96M
LUNG icon
37
Pulmonx
LUNG
$52.8M
$5.18M 0.44%
+75,000
New +$3.67M
EYPT icon
38
EyePoint Inc
EYPT
$1B
$4.61M 0.39%
+699,999
New +$3.27M
ANNX icon
39
Annexon
ANNX
$814M
$4M 0.34%
159,622
– –
BDTX icon
40
Black Diamond Therapeutics
BDTX
$101M
$3.96M 0.34%
123,465
– –
OBIO icon
41
Orchestra BioMed
OBIO
$231M
$3.84M 0.33%
300,000
– –
PCVX icon
42
Vaxcyte
PCVX
$7.88B
$3.72M 0.32%
+140,000
New +$5.2M
HRMY icon
43
Harmony Biosciences
HRMY
$2.07B
$3.62M 0.31%
100,000
-175,000
-64% -$7.06M
BMY.RT
44
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$3.48M 0.3%
5,050,000
-450,000
-8% -$959K
ELDN icon
45
Eledon Pharmaceuticals
ELDN
$262M
$3.45M 0.3%
+224,071
New +$4.27M
ITOS
46
DELISTED
iTeos Therapeutics
ITOS
$3.38M 0.29%
100,000
-200,000
-67% -$5.29M
OM icon
47
Outset Medical
OM
$87.5M
$2.84M 0.24%
3,333
-3,334
-50% -$2.57M
PANA.U
48
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
$2.55M 0.22%
200,000
– –
TNGX icon
49
Tango Therapeutics
TNGX
$4.34B
$2.29M 0.2%
200,000
– –
MLTX icon
50
MoonLake Immunotherapeutics
MLTX
$1.59B
$2.27M 0.19%
+200,000
New +$2.12M
1
2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q4 2020 Portfolio in Review

As of Q4 2020, Logos Global Management held 74 positions worth $1.17B, up 49% from $781M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Logos Global Management deployed $46M of net new capital in Q4 2020, opening 28 new positions and adding to 5 existing holdings. Its largest new stake was Olema Pharmaceuticals: 3,743,875 shares worth $180M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $72.5M trimmed.

  • Logos Global Management's largest Q4 2020 buy was Olema Pharmaceuticals: 3,743,875 shares worth $180M.
  • Logos Global Management added most to Cogent Biosciences in Q4 2020, an estimated $13.7M increase.
  • Logos Global Management's biggest Q4 2020 reduction was Keros Therapeutics, cutting an estimated $72.5M.
  • Logos Global Management fully exited Global Blood Therapeutics, Inc. in Q4 2020, selling an estimated $46.9M.
  • Logos Global Management's ten largest holdings make up 68% of its $1.17B portfolio in Q4 2020.
  • Logos Global Management opened 28 new positions and closed 15 in Q4 2020.
  • Logos Global Management's portfolio value rose 49% quarter-over-quarter to $1.17B.

Based on Logos Global Management's 13F filing for Q4 2020, filed 16 Feb 2021.